• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Rapid-Onset Treatment for Pedophilic Disorder

Rapid-Onset Treatment for Pedophilic Disorder

September 13, 2021
Anne Li, MD.
From The Carlat Hospital Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Anne Li, MD. Dr. Li has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Landgren V et al, JAMA Psychiatry 2020;77(9):897–905

Pedophilia—the sexual attraction to prepubescent children—has no clearly effective treatment. A common pharmacologic intervention is gonadotropin-releasing hormone (GRH) agonists, which lower testosterone through receptor desensitization. However, by producing an initial flare-up of testosterone, this treatment can increase aggression and libido, which limits intervention through GRH agonists to supervised correctional settings.

A recent study evaluated the efficacy of degarelix (Firmagon) for pedophilia. In contrast to GRH agonists, degarelix is a GRH antagonist and decreases testosterone to castration levels within three days without a testosterone flare-up. In a three-year study, researchers randomly assigned 52 men with pedophilic disorder to one of two conditions: degarelix (n = 26) or placebo (n = 26).

Participants in the treatment group received two subcutaneous doses of 120 mg degarelix acetate; those in the placebo group received similar-appearing injections of saline. All participants kept a diary and underwent structured interviews at baseline, two weeks, and 10 weeks. Researchers measured efficacy outcomes across five domains: pedophilic disorder as defined by DSM-5, sexual preoccupation, impaired self-regulation, low empathy, and self-rated risk of offending.

Participants receiving degarelix scored significantly lower than the placebo group in scores of pedophilic disorder and sexual preoccupation. However, there were no group differences in the domains of impaired self-regulation, low empathy, and self-rated risk of offending. Post-hoc analyses revealed that 58% of the degarelix group denied sexual attraction to minors at 10 weeks—much more than the placebo group, at only 12%.

Adverse events of degarelix included transient injection site reactions and hepatobiliary enzyme level elevations. Two participants (8%) in the degarelix group experienced transient suicidal ideation.

CHPR’s TAKE
Men who commit sexual offenses against children generally report struggling with their sexual urges for 10 years before committing a sexual crime (Knack N et al, Int Rev Psychiatry 2019;31(2):181–194). Degarelix did not improve self-regulation or empathy or reduce the self-rated risk of offending, but it reduced sexual attraction to minors, worked quickly, and was well tolerated. Given that we have few options to treat pedophilic disorder, this may be a helpful intervention.
Hospital Psychiatry
KEYWORDS degarelix pedophilic-disorder prepubescent-children sex-offenders
    Anne Li, MD.

    Clozapine for Conduct Disorder in Schizophrenia

    More from this author
    www.thecarlatreport.com
    Issue Date: September 13, 2021
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Agitation, CHPR, October-November-December 2021
    Note From the Editor-in-Chief
    IM Olanzapine Plus Benzodiazepines: Safe or Unsafe?
    Can We Treat Depression by Targeting Inflammation?
    Faster Refeeding of Patients With Anorexia Nervosa Appears Safe
    Melatonin vs Memantine for ECT-Related Cognitive Impairment
    Rapid-Onset Treatment for Pedophilic Disorder
    Medications to Rapidly Treat Psychotic Agitation
    Anticholinergic Drugs and Risk of Cognitive Impairment and Dementia
    Treating Agitation in Patients with Dementia
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.